Description
KPV is a short tripeptide studied in laboratory research involving inflammatory signalling, epithelial barrier function and tissue-response pathways.
Potential Benefits — Research Is Ongoing
Potential benefits are based on cell and animal research, including specialised delivery systems; human benefits of this presentation remain unconfirmed.
- Calmer inflammatory signalling: May help reduce excessive inflammatory activity.
- Gut-lining protection: May help protect intestinal tissue from inflammation-related damage.
- Intestinal recovery: May support a healthier environment for recovery of inflamed gut tissue.
- Skin-cell resilience: May help protect skin cells against inflammation triggered by environmental particles.
- Reduced inflammatory tissue stress: May help limit the cellular damage associated with overactive inflammatory pathways.
Research sources: KPV intestinal-inflammation study; KPV skin-cell study.
Research Overview
KPV is the Lys–Pro–Val tripeptide derived from the terminal region of alpha-melanocyte-stimulating hormone. Research has investigated its effects on inflammatory signalling in intestinal epithelial and immune cells, and in experimental mouse models of colitis. These are preclinical findings rather than established benefits in people.
Mechanism / Pathway
PepT1 is a transporter that moves small peptides into cells. The cited study links KPV uptake to reduced NF-kappaB-related inflammatory signalling. This model-specific mechanism does not establish that the same exposure or response occurs with a prefilled research pen.
Important Research Information
The cited work does not validate this product for treating bowel disease, skin conditions or systemic inflammation. Delivery route, peptide stability and tissue exposure matter, and human safety and efficacy of this presentation are not established by these experiments.
Published Research
- [1] Dalmasso et al. (2008): PepT1-mediated KPV uptake and intestinal inflammation.
- [2] Kannengiesser et al. (2008): KPV in murine models of inflammatory bowel disease.
Scientific Profile
- Identity: KPV / Lys–Pro–Val
- Structural class: Tripeptide corresponding to the terminal region of alpha-MSH
- Research pathway: PepT1-mediated uptake and inflammatory signalling in experimental models
- Evidence level: Cell and mouse studies; human benefits of this research presentation are not established
Research Areas
- Epithelial and immune-cell responses
- PepT1 transport and NF-kappaB-associated signalling
- Experimental intestinal inflammation and peptide-delivery limitations
Product Presentation
- Format: 3 mL prefilled disposable research pen
- Pen graduation: 300 clicks
- Research compound: KPV 10 mg
- Storage: Keep refrigerated at 2–8°C and protect from light
Research-Use Notice
KPV 10 mg: choosing the presentation
This page describes the prefilled pen format. Compare the separate KPV 10 mg Vial if you are checking packaging, contents or what is included. Each presentation has its own listing and label information.
The KPV 10 mg product guide provides supporting product information. The labelled amount is not a dosing instruction.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
A clinically validated contraindication list for this exact research presentation has not been established. That absence is not evidence of safety. Do not expose a person with a known allergy to a labelled ingredient or excipient.
Warnings & Precautions
This research presentation has not been established as safe for human administration. Do not use during pregnancy or breastfeeding, or in children. A serious medical condition, including cancer or significant liver or kidney disease, requires professional assessment; this page cannot establish suitability.
Possible Adverse Reactions
Reliable frequencies and a complete human adverse-reaction profile for this exact product are unavailable. Allergy, local irritation and contamination-related harm remain possible; absence of reports does not establish absence of risk.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. A clear appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: FDA research-peptide and compounding safety context. Information reviewed 20 October 2026.
Reviews
There are no reviews yet.